1046497-49-7

Upstream product

• 1208428-03-8 (5-hydroxymethyl-isoxazol-3-yl)-diphenyl-methanol 
• 79654-39-0 (5-methyl-isoxazol-3-yl)-diphenyl-methanol 

Downstream Products

• 1046497-51-1 (5-methylaminomethyl-isoxazol-3-yl)-diphenyl-methanol 
• 1208427-02-4 (R)-3-(3-fluoro-phenylsulfanyl)-1-[3-(hydroxy-diphenyl-methyl)-isoxazol-5-ylmethyl]-1-azonia-bicyclo[2.2.2]octane bromide 
• 1208255-03-1 (R)-3-(3-fluoro-4-methyl-phenoxy)-1-[3-(hydroxy-diphenyl-methyl)-isoxazol-5-ylmethyl]-1-azonia-bicyclo[2.2.2]octane bromide 

Relevant academic research and scientific papers

NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA-2 RECEPTORS

The present invention relates to named compounds of the formula (I) having both M3 receptor antagonist and β2 agonist activity; compositions comprising such compounds; the use of such compounds in therapy (such as respiratory tract disorders); and a metho

HETEROCYCLIC COMPOUNDS USED IN THE TREATMENT OF DISEASES WHERE ENHANCED M3 RECEPTOR ACTIVATION IS IMPLICATED

The invention provides named compounds of formula (I), pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions and their use in in the treatment of diseases where enhanced M3 receptor activation is implicated.

PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT

The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is selected from a phosphodiesterase inhibitor, a modulator of chemokine receptor function, an inhibitor of kinase function, a protease inhibitor, a steroidal glucocorticoid receptor agonist, a non-steroidal glucocorticoid receptor agonist and a purinoceptor antagonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.